[
  {
    "ts": "2025-09-06T11:36:11+00:00",
    "headline": "Why Biogen (BIIB) Is Up 6.4% After At-Home Alzheimer’s Therapy and Dravet Data Updates",
    "summary": "In recent days, Biogen and its partners announced the FDA approval and October launch of LEQEMBI Iqlik, a subcutaneous, at-home formulation for early Alzheimer's disease, along with new positive clinical data for zorevunersen in Dravet syndrome presented at a major epilepsy congress. These updates highlight growing momentum in the advancement of therapies for challenging neurological conditions, potentially expanding Biogen's addressable patient population and reinforcing the company’s focus...",
    "url": "https://finance.yahoo.com/news/why-biogen-biib-6-4-113611546.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "77c07b38-6f89-3b1e-a89a-f80552365bd9",
      "content": {
        "id": "77c07b38-6f89-3b1e-a89a-f80552365bd9",
        "contentType": "STORY",
        "title": "Why Biogen (BIIB) Is Up 6.4% After At-Home Alzheimer’s Therapy and Dravet Data Updates",
        "description": "",
        "summary": "In recent days, Biogen and its partners announced the FDA approval and October launch of LEQEMBI Iqlik, a subcutaneous, at-home formulation for early Alzheimer's disease, along with new positive clinical data for zorevunersen in Dravet syndrome presented at a major epilepsy congress. These updates highlight growing momentum in the advancement of therapies for challenging neurological conditions, potentially expanding Biogen's addressable patient population and reinforcing the company’s focus...",
        "pubDate": "2025-09-06T11:36:11Z",
        "displayTime": "2025-09-06T11:36:11Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I2k3PKJsWIEX9xgEQz8JwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmSjpFKmBAT61w1lG5.BLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-biogen-biib-6-4-113611546.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-biogen-biib-6-4-113611546.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]